PubMed · 9865023
The source did not provide an abstract. Follow the original record for more information.
Explore connections, maps & timelines
O I Iakhontova, Ia M Rutgaĭzer, L N Valenkevich. 1998. [Jaundice].. https://pubmed.ncbi.nlm.nih.gov/9865023/
Cite the original work for its findings. Save a collection to share your selection of sources.
KEEP EXPLORING
Ursodeoxycholic acid is a hydrophilic bile acid that under normal circumstances represents a small fraction of the bile acid pool in humans. It is effective in dissolving cholesterol gallstones in appropriately selected patients. Ursodeoxycholic acid improves serum alkaline phosphatase and aminotransferase levels in primary biliary cirrhosis, but its effects on rates of liver transplantation and death are less certain. Ursodeoxycholic acid has had promising [corrected] effects in several other cholestatic liver diseases, such as cystic fibrosis and intrahepatic cholestasis of pregnancy, but data are too preliminary to make recommendations about its routine use in these conditions. Its effects are mediated by amelioration of damage to cell membranes caused by retained toxic bile acids. Ursodeoxycholic acid improves biliary secretion of bile acids, may improve bile flow, and it has immunomodulatory properties that may reduce immune-mediated liver damage. However, its use in the treatment of cholestatic liver disease remains uncertain pending additional randomized trials.
An analysis of the recent medical literature on therapeutic biliary endoscopy shows continuing developments in technique, as well as an effort to obtain objective data on the long-term outcomes with different clinical applications. There are still too few studies analyzing costs, and these should be encouraged in the immediate future.
Explore the source record for details and available documents.